Report Overview:
Nasal Spray Live Attenuated Influenza Vaccine (LAIV) is a vaccine designed to protect individuals against the influenza virus. Unlike traditional injectable vaccines that contain inactivated virus particles, the LAIV uses a weakened, live version of the influenza virus. This live virus is attenuated, meaning it has been modified to significantly reduce its virulence while maintaining its ability to stimulate the immune system effectively. LAIV is typically administered through the nose, offering an alternative to injectable flu vaccines. FluMist is one of the most recognized brands in this category, gaining popularity due to its ease of use and non-invasive nature.
Market Value:
The global Nasal Spray Live Attenuated Influenza Vaccine Market for Nasal Spray Live Attenuated Influenza Vaccine is poised for significant growth.
As of 2024, the market size is estimated at USD 718.50 million, and it is projected to reach USD 1,216.18 million by 2032, growing at a CAGR of 6.80% during the forecast period. CAGR of 6.80%
By Types:
• Trivalent Flu Vaccine
• Quadrivalent Flu Vaccine
By Applications: Hospital
Clinic
Public Health Agency
Key players include:
• Sanofi Pasteur
• AstraZeneca
• CSL
• Abbott
• GlaxoSmithKline
• Serum Institute
• Including or Excluding key companies relevant to your analysis.
